<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; inhaler</title>
	<atom:link href="http://www.tapanray.in/tag/inhaler/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Create Greater Patient–Value To Excel With Repurposed Covid Brands</title>
		<link>http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-greater-patient-value-to-excel-with-repurposed-covid-brands</link>
		<comments>http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/#comments</comments>
		<pubDate>Mon, 23 Nov 2020 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[antivirals]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inhaler]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[novel]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[repurposed]]></category>
		<category><![CDATA[segments]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[systems]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10335</guid>
		<description><![CDATA[Regular introduction of new molecules, line extensions or a Novel Drug delivery System (NDDS) has remained the life blood for pharma to rejuvenate a company’s product portfolio for driving organizational growth. But, Covid’s unprecedented and devastating assault on human lives &#8230; <a href="http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>2015: Pharma Industry Achieved Some, Could Achieve Some More</title>
		<link>http://www.tapanray.in/2015-pharma-industry-achieved-some-could-achieve-some-more/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=2015-pharma-industry-achieved-some-could-achieve-some-more</link>
		<comments>http://www.tapanray.in/2015-pharma-industry-achieved-some-could-achieve-some-more/#comments</comments>
		<pubDate>Mon, 04 Jan 2016 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[achieved]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[Google]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[inhaler]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[Novo Nordisk]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research. delivery]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[smart]]></category>
		<category><![CDATA[Social media]]></category>
		<category><![CDATA[Some]]></category>
		<category><![CDATA[systems]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7378</guid>
		<description><![CDATA[Wish You And All Your Near And Dear Ones Peace, Happiness, Good Health And Prosperity in The Brand New Year 2016  The year 2015 witnessed several noteworthy developments in the pharma industry, just as many other years before. That said, &#8230; <a href="http://www.tapanray.in/2015-pharma-industry-achieved-some-could-achieve-some-more/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/2015-pharma-industry-achieved-some-could-achieve-some-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does Patent Expiry Matter Less For Difficult To Copy Drugs?</title>
		<link>http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-patent-expiry-matter-less-for-difficult-to-copy-drugs</link>
		<comments>http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/#comments</comments>
		<pubDate>Mon, 08 Sep 2014 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advair]]></category>
		<category><![CDATA[aerosol]]></category>
		<category><![CDATA[AirFluSal Forspiro]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[copy]]></category>
		<category><![CDATA[difficult]]></category>
		<category><![CDATA[Diskus]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inhaler]]></category>
		<category><![CDATA[less]]></category>
		<category><![CDATA[matters]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[ParaIV]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Seretide]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5865</guid>
		<description><![CDATA[“Patent expiry matters much less for difficult to copy drugs”. Not so long ago, this is what many used to believe in the pharma industry. However, looking at the current trend involving the tech savvy generic players, it appears, gone &#8230; <a href="http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
